Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase-Reference-Cited by-同舟云学术

Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase

Published:2018-07-10 Issue:20 Volume:36 Page:2101-2104
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Holstein Sarah A.¹,Hillengass Jens¹,McCarthy Philip L.¹

Affiliation:

1. Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; and Jens Hillengass and Philip L. McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.77.9637

Reference45 articles.

1. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

2. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

3. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM

4. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

5. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study;Blood Cancer Journal;2023-03-24

2. Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators;European Journal of Medicinal Chemistry;2023-02

3. A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022;Expert Review of Anticancer Therapy;2022-05-03

4. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer;Bioorganic Chemistry;2022-02

5. Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population;Technology in Cancer Research & Treatment;2022-01